258 related articles for article (PubMed ID: 23073619)
1. Current and future management of NK/T-cell lymphoma based on clinical trials.
Yamaguchi M
Int J Hematol; 2012 Nov; 96(5):562-71. PubMed ID: 23073619
[TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
4. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
[TBL] [Abstract][Full Text] [Related]
5. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
Makita S; Tobinai K
Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
[TBL] [Abstract][Full Text] [Related]
7. Pediatric nasal NK/T-cell lymphoma microscopically mimicking carcinoma.
Sánchez-Romero C; Paes de Almeida O; Díaz Molina JP; Carlos R
Int J Dermatol; 2020 Mar; 59(3):373-376. PubMed ID: 31729756
[No Abstract] [Full Text] [Related]
8. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
10. NK/T Cell Lymphoma: Updates in Therapy.
Suzuki R
Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
13. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
[TBL] [Abstract][Full Text] [Related]
14. Current treatment approaches for NK/T-cell lymphoma.
Yamaguchi M; Miyazaki K
J Clin Exp Hematop; 2017 Dec; 57(3):98-108. PubMed ID: 28679966
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of NK/T-cell lymphoma: current situations and prospectives].
Yamaguchi M
Rinsho Ketsueki; 2018; 59(5):588-593. PubMed ID: 29877250
[TBL] [Abstract][Full Text] [Related]
16. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
17. Management of advanced NK/T-cell lymphoma.
Tse E; Kwong YL
Curr Hematol Malig Rep; 2014 Sep; 9(3):233-42. PubMed ID: 24924658
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma.
Suzuki R
Semin Hematol; 2014 Jan; 51(1):42-51. PubMed ID: 24468315
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]